Table 1. Clinicopathological characteristics of patient tumors (n = 65).
| Stage III IBC | mIBC | P- value | |||
|---|---|---|---|---|---|
| N | % | N | % | ||
| All | 21 | 100.0 | 44 | 100.0 | NA |
| CTC per 7.5 mL of blood | |||||
| ≥ 1 | 7 | 33.3 | 33 | 75.0 | 0.002 |
| ≥ 5 | 1 | 4.8 | 22 | 50.0 | 0.001 |
| Grade | |||||
| 1 and 2 | 9 | 42.9 | 14 | 31.8 | 0.58 |
| 3 | 12 | 57.1 | 29 | 65.9 | |
| unknown | 0 | 0.0 | 1 | 2.3 | |
| Histology | |||||
| Invasive ductal carcinoma | 18 | 85.7 | 36 | 81.8 | 0.74 |
| Other | 3 | 14.3 | 8 | 18.2 | |
| ER/PR status | |||||
| Negative for both | 6 | 28.6 | 24 | 54.5 | 0.07 |
| Positive for either | 15 | 71.4 | 20 | 45.5 | |
| HER2 status | |||||
| Amplified | 10 | 47.6 | 14 | 31.8 | 0.78 |
| Normal | 11 | 52.4 | 30 | 68.2 | |
| ER/PR and HER2/neu status | |||||
| Triple receptor negative | 5 | 23.8 | 17 | 38.6 | 0.28 |
| Non-triple receptor negative | 16 | 76.2 | 27 | 61.4 | |
| Sites of metastases | |||||
| Non-visceral | NA | NA | 27 | 61.4 | NA |
| Visceral | NA | NA | 17 | 38.6 | |
| Bone metastases | |||||
| Present | NA | NA | 23 | 52.3 | NA |
| Absent | NA | NA | 21 | 47.7 | |
| No. of metastasis | |||||
| 1 | NA | NA | 21 | 47.7 | NA |
| ≥2 | NA | NA | 23 | 52.3 | |
| Treatment | |||||
| Treatment naïve | 21 | 100.0 | 14 | 31.8 | NA |
| Pretreated | 0 | 0.0 | 30 | 68.2 | |
Abbreviations: NA, not applicable; ER, estrogen receptor; PR, progesterone receptor.